Loading
Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.
Do-Youn Oh is Professor of Internal Medicine at Seoul National University Hospital, specialising in gastrointestinal and hepatobiliary oncology. She was principal investigator of TOPAZ-1, the trial that added the immunotherapy durvalumab to first-line gemcitabine plus cisplatin for advanced biliary tract cancer, the first phase 3 in more than a decade to improve outcomes in that disease. Her publications include the TOPAZ-1 report on durvalumab plus gemcitabine and cisplatin. She runs pancreatic and biliary clinical trials at Seoul National University Hospital, with interests in immunotherapy for biliary tract cancer and pancreatic cancer.
The IHC 3+ subgroup result is why the tumour-agnostic label is written at 3+ and not 2+, and why a gallbladder cancer with a strong HER2 stain now has two on-label choices (zanidatamab, trastuzumab deruxtecan) after chemotherapy. Lung toxicity again ran higher than in breast cancer.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares NEJM Evidence, TOPAZ-1, Durvalumab.
Shares TOPAZ-1, Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares TOPAZ-1, Gemcitabine + cisplatin, Biliary tract cancer (cholangiocarcinoma).
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares NEJM Evidence, Durvalumab.